In a nutshell, unlike traditional immunotherapy, which targets solely CRC patients in late stages with MSI-H, scRNA-seq immune transcriptional studies offer an alternative option for precision medicine by targeting the Wnt signalling pathway via BCL9 depletion. Here, BCL9 is linked to colorectal carcinoma.